| 1/2 | Câncer Mundim FGL, Logullo AF. Role of the Expression of the Tyrosine Kinase Receptor KIT in Invasive Ductal Carcinomas of the Breast: A Review. Applied Cancer Research, São Paulo: Tecmedd, v.29, n.2, p. 50-7, 2009. ISSN 1980-5578. Disponível em: http://accamargo.phlnet.com.br/applied/ACR2009292p.50-7.pdf |
| 2/2 | US=67 / Biol/Mol Denis GV. Imatinib mesylate (gleevec) and the emergence of chemotherapeutic drug-resistant mutations. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 545-57. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. QUIMIOTERAPICOS; MUTACOES; RESISTENCIA AOS MEDICAMENTOS; MESILATO DE IMATINIBE; GLEEVEC; STI-571; LEUCEMIA MIELOGENA CRONICA; TUMOR ESTROMAL GASTROINTESTINAL; BCR-ABL; C-KIT; FATOR DE CELULA-TRONCO; BIOLOGIA ESTRUTURAL |